Glenmark Pharmaceuticals Ltd — Quarterly Results & Earnings

₹2131.70

+0.82%

Profit Growth YoY333.45%Latest quarter

Sales Growth YoY76.10%Latest quarter

Sales CAGR 5Y4.60%5 year compound

Profit CAGR 5Y11.77%5 year compound

📋

Quarterly Performance

YoY Profit Growth+333.45%

🔥 Exceptional growth

YoY Sales Growth+76.10%

🔥 Exceptional growth

OPM 5Y Average

Operating profit margin

16.68%

EPS Growth 5Y

11.77%

Interest Coverage

Higher = safer debt servicing

15.81

ROE

15.79%

ROCE

19.40%

💡

Growth Analysis

Glenmark Pharmaceuticals Ltd reported YoY profit growth of 333.45% and revenue growth of 76.10% in the latest quarter. Double-digit profit growth above 20% is exceptional — indicates strong business momentum. Over 5 years, sales compounded at 4.60% and profits at 11.77% annually. Consistent growth over 4-8 quarters is more meaningful than any single quarter. Educational data only.

More on Glenmark Pharmaceuticals Ltd

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.